NEW YORK (GenomeWeb News) – Response Biomedical this week said that it has consolidated its stock on a 10 for one basis. The Vancouver, BC-based molecular diagnostics company said that the consolidation applies to all of its common shares, stock options, and warrants. Following the consolidation, Response Biomedical has 25,467,200 common shares outstanding.
Barclays Capital this week raised its price target on Sequenom's stock to $9 from $7 and reiterated its 'overweight' rating on the shares. C. Anthony Butler, the analyst for Barclays that covers Sequenom, said that there is increased confidence that the firm will report positive data this summer on its Down syndrome test.
The Allen Institute for Brain Science this week launched the Allen Human Brain Atlas, a publicly available online atlas charting gene expression in the human brain. The Atlas integrates anatomic and genomic information to create a searchable, three-dimensional map of gene activity in the brain, and is available here.
The Paterson Institute for Cancer Research has licensed Dotmatics' complete range of drug discovery informatics solutions. Dotmatics said that suite includes its Browser, Vortex, Studies, Register, gateway, Pinpoint, and Nucleus products.
Japan research institute Riken said this week that its Bioinformatics And Systems Engineering division has launched its first ever International Rational Genome Design Contest (GenoCon). According to Riken, contestants must make effective use of genomic and protein data contained in SciNeS database clusters to design DNA sequences that improve plant physiology. In the first GenoCon, contestants are asked to design a DNA sequence conferring to the model organism Arabidopsis thaliana the functionality to effectively eliminate and detoxify airborne formaldehyde.
GenoCon began accepting entries to the contest May 25 on its website.